PART 01: Executive summary PART 02: Scope of the report PART 03: Research Methodology PART 04: Introduction • Market outline PART 05: Market landscape • Market overview • Five forces analysis PART 06: Pipeline landscape PART 07: Drug class segmentation • Global liver disease treatment market by anti-viral drugs • Global liver disease treatment market by corticosteroids • Global liver disease treatment market by other drugs • Global liver disease treatment market by vaccines PART 08: Market segmentation by disease type • ARLD • NAFLD • Hepatitis • PBC • Hemochromatosis PART 09: Geographical segmentation • Liver disease treatment market in Americas • Liver disease treatment market in EMEA • Liver disease treatment market in APAC PART 10: Decision framework PART 11: Drivers and challenges • Market drivers • Market challenges PART 12: Market trends • Rise in awareness • Increase in R&D activities for liver cirrhosis medication • Increasing collaborations and M&A PART 13: Vendor landscape • Competitive scenario PART 14: Key vendor analysis • F. Hoffmann-la Roche • Gilead • GlaxoSmithKline • Merck • Other prominent vendors PART 15: Appendix • List of abbreviations List of Exhibits Exhibit 01: Functions of liver Exhibit 02: Types of liver diseases Exhibit 03: Global liver disease treatment market Exhibit 04: Global liver disease treatment market 2016-2021 ($ billions) Exhibit 05: Opportunity analysis of global liver disease drugs market Exhibit 06: Five forces analysis Exhibit 07: Pipeline summary based on vendors Exhibit 08: Key clinical trials Exhibit 09: Global liver disease market by drug class Exhibit 10: Global liver disease treatment market by drug class 2016 and 2021 Exhibit 11: Global liver disease treatment market by anti-viral drugs 2016-2021 ($ billions) Exhibit 12: HIV treatment regimen approved by FDA Exhibit 13: Global liver disease treatment market by corticosteroids 2016-2021 ($ billions) Exhibit 14: Global liver disease treatment market by other drugs 2016-2021 ($ billions) Exhibit 15: Global liver disease treatment market by vaccines 2016-2021 ($ billions) Exhibit 16: Vaccination coverage for birth dose of hepatitis B vaccine in various regions 2013 Exhibit 17: Vaccination coverage for three doses of hepatitis B vaccine in various regions 2013 Exhibit 18: Global liver disease treatment market by disease type Exhibit 19: Stages of ARLD Exhibit 20: Deaths due to ARLD in US 2014 Exhibit 21: Stages of NAFLD Exhibit 22: Types of hepatitis Exhibit 23: Mode of transmission and incubation period of different types of hepatitis Exhibit 24: Hepatitis A: Key marketed drugs Exhibit 25: Hepatitis B: Key marketed drugs Exhibit 26: Hepatitis C: Key marketed drugs Exhibit 27: Medications for symptoms of PBC Exhibit 28: Global liver disease treatment market by geography 2016 and 2021 Exhibit 29: Global liver disease treatment market by geography 2016-2021 ($ billions) Exhibit 30: Market scenario in Americas Exhibit 31: Liver disease treatment market in Americas 2016-2021 ($ billions) Exhibit 32: Factors contributing to liver cancer in US Exhibit 33: Hepatitis infection scenario in US, 2015-2016 Exhibit 34: Market scenario in EMEA Exhibit 35: Liver disease treatment market in EMEA 2016-2021 ($ billions) Exhibit 36: Market scenario in APAC Exhibit 37: Liver disease treatment market in APAC 2016-2021 ($ billions) Exhibit 38: Top Asian countries in terms of population with diabetes Exhibit 39: Countries with large populations without adequate sanitation 2014 Exhibit 40: Effects of lifestyle diseases on liver Exhibit 41: Competitive structure analysis of global liver disease treatment market 2016 Exhibit 42: Strategic success factors of companies in global liver disease treatment market Exhibit 43: F. Hoffmann-la Roche: Key highlights Exhibit 44: F. Hoffmann-la Roche: Strength assessment Exhibit 45: F. Hoffmann-la Roche: Strategy assessment Exhibit 46: F. Hoffmann-la Roche: Opportunity assessment Exhibit 47: Gilead: Key highlights Exhibit 48: Gilead: Strength assessment Exhibit 49: Gilead: Strategy assessment Exhibit 50: Gilead: Opportunity assessment Exhibit 51: GlaxoSmithKline: Key highlights Exhibit 52: GlaxoSmithKline: Strength assessment Exhibit 53: GlaxoSmithKline: Strategy assessment Exhibit 54: GlaxoSmithKline: Opportunity assessment Exhibit 55: Merck: Key highlights Exhibit 56: Merck: Strength assessment Exhibit 57: Merck: Strategy assessment Exhibit 58: Merck: Opportunity assessment

F. Hoffmann-la Roche, Gilead, GlaxoSmithKline, Merck, ristol-Myers Squibb, Johnson and Johnson, Novartis, Salix Pharmaceuticals, and Vertex Pharmaceuticals.